TURKOVAC
TURKOVAC[1] (pronunciation: ['tɜ:rkəvæk]) (temporarily named as ERUCOV-VAC[2]) is a COVID-19 vaccine candidate developed by Health Institutes of Turkey and Erciyes University.[3][4]
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Other names | ERUCOV-VAC |
Routes of administration | Intramuscular |
ReferencesEdit
- ^ Cakmak, Busra Nur (22 June 2021). "Turkey names home-grown COVID-19 jab Turkovac". Anadolu Agency.
- ^ "Domestic COVID-19 jab Turkovac begins Phase 3 trials in Turkey". Daily Sabah. 22 June 2021. Retrieved 23 June 2021.
- ^ "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC (ERUCOV-VAC)". clinicaltrials.gov. United States National Library of Medicine. 31 December 2020. Retrieved 21 March 2021.
- ^ "Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19". clinicaltrials.gov. United States National Library of Medicine. 30 March 2021. Retrieved 4 April 2021.
Scholia has a profile for ERUCOV-VAC (Q106532118). |